



# **Drug Discovery Today: Technologies**

Editors-in-Chief


Kelvin Lam – Simplex Pharma Advisors, Inc., Boston, MA, USA Henk Timmerman – Vrije Universiteit, The Netherlands

TECHNOLOGIES

Crispr/Cas9 HR

# Developing precision medicine using scarless genome editing of human pluripotent stem cells

Benjamin Steyer<sup>1</sup>, Evan Cory<sup>1</sup>, Krishanu Saha<sup>1,2,\*</sup>



<sup>&</sup>lt;sup>2</sup>Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA



Many avenues exist for human pluripotent stem cells (hPSCs) to impact medical care, but they may have their greatest impact on the development of precision medicine. Recent advances in genome editing and stem cell technology have enabled construction of clinically-relevant, genotype-specific "disease-in-a-dish" models. In this review, we outline the use of genome-edited hPSCs in precision disease modeling and drug screening as well as describe methodological advances in scarless genome editing. Scarless genome-editing approaches are attractive for genotype-specific disease modeling as only the intended DNA base-pair edits are incorporated without additional genomic modification. Emerging evidentiary standards for development and approval of precision therapies are likely to increase application of disease models derived from genome-edited hPSCs.

# Introduction

Improving pre-clinical disease models to more faithfully predict clinical effectiveness and identify toxicity is anticipated to lower the current 90% clinical trial failure rate [1]. This is especially important in the context of **precision medicine**, because disease models need to be tailored to specific **biomarkers** or genetic variations (bolded terms in

#### Section editor:

Dr. Milena Bellin – Department of Anatomy and Embryology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC, Leiden, The Netherlands.

Box 1). Human **pluripotent** stem cell (hPSC) based disease models are good candidates to meet this challenge, since they can be tailored through genome editing for the rigorous evaluation of genotype-to-disease phenotype relationships in biologically relevant human cells.

Human induced pluripotent stem cells (hiPSCs) are **reprogrammed** from routine clinical samples (e.g., blood draws, skin biopsies) and can be reliably expanded in culture [2,3]. Importantly, hiPSCs retain their patient specific genotype throughout the reprogramming process. This feature enables hiPSCs to be differentiated towards disease affected cell types in order to recapitulate a patient's disease phenotype [4] and to evaluate patient-specific therapeutic response in a controlled cell culture environment [5] (Fig. 1A). Stem cell-derived disease models are most applicable for modeling diseases with quantifiable cell autonomous disease phenotypes observed in well-defined cells. With continued advancement of cell differentiation protocols, the "disease-ina-dish" paradigm has been applied to an array of neurodegenerative, cardiovascular, and other diseases [6].

As the process of reprogramming cells has become more efficient, bio-banks of hiPSC cohorts that are disease specific or representative of the general population have been created

<sup>\*</sup>Corresponding author: K. Saha (ksaha@wisc.edu)




Fig. 1. Paradigms of stem cell disease modeling for therapeutic screening. (A) Patient-specific disease in a dish models. Unaffected siblings share only ~50% genetic inheritance with affected patients and the field has largely moved towards isogenic controls to validate phenotypic outputs (diseased vs. healthy). These screens are not generalizable (i.e., can only inform treatment for a specific patient) in isolation due to potentially confounding effects of background gene modifiers. (B) hiPSC cohort clinical trial in a dish. Cohorts of bio-banked iPSCs, with various disease associated variants/biomarkers and various genetic backgrounds, are differentiated and cell line to phenotypic recovery outcomes are identified for candidate drugs. Computational analysis is performed to identify externally valid (i.e. results can be used to inform treatment for patients not in cohort) drug specific variant/biomarker to phenotypic recovery correlations. Cohort approaches are ideal for diseases with complex inheritance and access to patient hiPSCs. (C) High-throughput, variant-specific therapeutic screening. Disease associated variants can be introduced into a well-defined hPSC line with scarless genome editing to create an array of isogenic cell lines. Direct assessment of variant/biomarker specific therapeutic response relationships can be observed with high-content screening (or other high-throughput) assays. This approach is ideal for rare monogenic diseases where access to patient-specific hiPSCs is limited.

to conduct so called "clinical trials in a dish" (Fig. 1B) (reviewed by Warren and Cowan [7]). A recent study by Burridge et al. [8] revealed that hiPSC derived cardiomyocytes faithfully recapitulated doxyrubicin induced cardiotoxicity phenotypes in breast cancer patients with or without cardiotoxicity after doxyrubicin treatment. Patient derived hiPSC approaches like this are well suited to diseases with multigenic or complex inheritance patterns.

Initial disease models utilized hiPSCs from unaffected siblings to ensure that observed cellular phenotypes were disease specific (Fig. 1A, top). However, unaffected siblings are incomplete controls—sibling pairs have roughly 50% shared parental inheritance due to chromosomal segregation and crossover in meiosis. To validate disease-associated variants, the field has utilized genome editing techniques to correct patient mutations to wildtype variants (Fig. 1A, bottom). These patient-derived, gene-corrected pairs of cells differ only at the edited locus and are referred to as isogenic cell lines. Isogenic cell lines can be used to model patient specific disease mechanisms [9] and identify personalized therapy [10]. However, the resources required to scale this approach are prohibitive. To efficiently realize value from precision medicine, methodologies that can predict universal disease variant to treatment outcome correlations should be prioritized.

A more scalable genome-edited disease modeling approach involves introduction of disease specific mutations into well-characterized healthy hPSC lines with known genetic background (Fig. 1C). Using this approach, an array of unique disease-associated variants can be rationally engineered into the hPSCs. This eliminates the need to acquire hiPSCs from

# Box I. Key terms.

**Precision medicine**—Disease prevention and treatment that considers differences in patient's genes, environments, and lifestyles.

**Biomarker**—a genomic variant or phenotypic trait that is informative for predicting specific disease progression or treatment outcome.

**Pluripotent**—Capable of giving rise to all cell types of the body. **Reprogram**—the process of reverting mature somatic cells to a pluripotent or stem-like state. this can now be accomplished using non-integrating vectors.

**Isogenic cell lines**—Cell lines whose genetic makeup only differs at a specific locus.

**Scarless**—a targeted genome modification where only the intended DNA base-pair edits are incorporated without permanent integration of additional DNA sequences.

**CRISPR**—Short for clustered regularly interspaced short palindromic repeats.

Non-homologous end joining (NHEJ)—an error prone DNA repair process where double strand breaks are directly ligated, commonly resulting in insertion or deletion mutations.

Homology Directed Repair (HDR)—a precise DNA repair process in which cells repair double strand breaks in DNA by using a homologous DNA template (usually the homologous chromosome). this process can be co-opted to engineer-in specific sequences by delivering synthetic DNA donors with homology arms.

patients with rare variants where the ability to perform a new screen for each individual is not feasible. Instead gene-variant targeted therapies can be screened in advance. Wang et al. demonstrated the value of this approach by introducing disease associated variants of Barth syndrome in normal or unaffected iPSCs [11]. For diseases with primarily monogenic inheritance, this technique enables validation of the causality of disease associated variants and high-throughput screening of genotype-specific therapies.

In this review, we detail methods for **scarless**, or knock-in/ footprint free, precision genome editing of hPSCs. Scarless methods are named to distinguish them from "genetic scarring" methods that permanently integrate additional sequences into the genome that may impact precise disease phenotypes in undefined ways [12,13]. We end with a forecast of how genome-edited hPSC derived models could integrate into precision drug development.

# Precision genome editing with CRISPR

**CRISPR** has emerged as the workhorse of the genome editing field. The most common variant employs a CRISPR associated endonuclease, Cas9, and a short, single-guide RNA (sgRNA) to enable targeted double strand breaks (DSBs) in genomic DNA [14,15] (Fig. 2). DSBs are primarily repaired via **non-homologous end joining** (NHEJ) and **homology directed repair** (HDR). NHEJ requires no template for repair and results in a wide spectrum of insertion and deletion (indel) mutations. These mutations often result in loss of gene function, but effects of undefined gene products may confound disease modeling in unanticipated ways [16]. Conversely, HDR requires a repair template (usually the homologous chromosome) which is used for error-free repair in eukaryotic cells [17].

Delivering synthetic "donor" DNA, along with the CRISPR/Cas9 system, can co-opt the cell's intrinsic HDR machinery for introduction or correction of mutations, or introduction of synthetic genes [18,19]. Unfortunately, the overall efficiency of HDR is low (<10%) in hPSCs, so integrated drug selection cassettes were initially used to improve the efficiency of identifying edited clones [20]. However, a portion of the cassette sequence often remains integrated which may impact mRNA processing and/or protein translation in undefined ways [12,13]. While there are clear advantages of scarless genome-editing for precision hPSC disease modeling, a major limitation has been the low overall efficiency of these methods. To address this challenge, the field had focused in several major areas (Fig. 2, see also Table 1): increasing overall (NHEJ and HDR) genome editing (Section Improving overall genome editing efficiency), increasing ratio of HDR to NHEJ (Section Increasing HDR to NHEJ ratio), and improving selection of genome-edited clones (Section Identifying precisely-edited clones from a mixed population).




Fig. 2. Schematic of Cas9-induced DSB repair and focus areas for improving precision editing. Cas9 endonuclease is targeted to a specific locus in the human genome via a single guide RNA (sgRNA). Cas9 makes double strand breaks (DSBs) that are repaired via error prone non-homologous end joining (NHEJ) or precise homology directed repair (HDR). Scarless gene editing is facilitated by encoding desired edits on a plasmid or a double or single stranded linear donor DNA template (single stranded oligonucleotide DNA, ``ssODN'' shown here). NHEJ occurs more frequently than HDR in hPSCs. To facilitate increased precise and scarless HDR mediated genome editing, the field has focused primarily on: (1) increasing overall (NHEJ and HDR) genome editing, (2) increasing ratio of HDR to NHEJ, and (3) improving selection of genome-edited clones.

#### Improving overall genome editing efficiency

The level of intracellular Cas9 expression appears to represent a universal limiting step in genome editing [21–23]. Improvements to Cas9 delivery, or enrichment of cells with high Cas9 expression, have yielded improved editing outcomes. Cas9 can be stably integrated into a parental cell line or can be transiently delivered to cells during each new editing workflow. Generating a parental cell line with conditional or inducible Cas9 expression [22,24–27] has been shown to yield NHEJ efficiencies of up to 60% and precise HDR efficiencies up to 40%. The limitation of these methods is that the Cas9 construct is either permanently integrated [24,25] or must be later removed with a subsequent reagent delivery and/or clonal selection step [22,26] to achieve scarless editing. These methods are valuable when a single parental cell line will be used to generate many unique genotype specific cell lines.

Conversely, transient delivery of Cas9 is more applicable when a variety of cell lines must be edited (e.g., creating isogenic controls for bio-banked hiPSCs [7]), where prior generation of many stable lines would be too cumbersome. Cas9 can be delivered as a recombinant protein pre-complexed with sgRNA or encoded as mRNA or within a plasmid. Plasmid reagents have been used most extensively for hiPSC disease modeling applications, because co-expression of selectable markers from the plasmid can be used to enrich for Cas9 expressing cells. Plasmids that encode a viral 2A "ribosomal skip" peptide can be used to express GFP or a puromycin resistance gene in stoichiometric proportion to Cas9 [28– 30]. These plasmids enable enrichment of Cas9 expressing cells based on fluorescence assisted cell sorting (FACS) or puromycin selection. Single cell FACS can be challenging in hPSCs because of contamination risks and the variable

Table 1. Summary of recent strategies for precision genome editing. Examples were selected based on relevance to scarless genome editing in hPSCs and are not exhaustive.				
Method	Advantages	Disadvantages	Examples	
I.Improvingoverall genome editing efficiency				
A. Increase Cas9 expression				
Stable inducible Cas9 expression	- Cas9 can be integrated into AAVS or other safe	- Not scarless.	[24,25]	
	harbor loci under control of a Tet On promoter.	- Concern for higher probability of off-target DSBs.		
	- High Efficiency NHEJ and HDR.	- Line must be generated before other editing.		
Non-permanent constitutive or inducible	- Cas9 expressed between piggyBac or on episomal	- Concern for higher probability of off-target DSBs.	[22,26]	
Cas9 expression	plasmid.	- Line must be generated before other editing.		
	- High efficiency and scarless after Cas9 removed.			
Enrich for Transient Cas9 Expression	- Plasmid vectors enable enrichment for cells with	- Some concern for higher probability of off-target	[31,46]	
	high Cas9 expression.	DSBs.		
	- Do not need to create Cas9 cell line before each	- Lower efficiency vs inducible stable Cas9.		
	experiment.			
2. Increasing HDR to NHEJ ratio				
A. Cell cycle control				
Controlled timing of Cas9 delivery	- Cell cycle checkpoint blockers are used to sync	- Titration of checkpoint blockers is needed for each	[37]	
	cells.	cell line.		
	- Cas9 protein can be delivered to cells when synced	- HDR Efficiency gains are only		
	in a pro-HDR state.	I–2%.		
Cell cycle selective degradation of Cas9	- Geminin peptide conjugated to Cas9 causes Cas9	- Requires cloning of specialized Cas9 vector (not	[38]	
	degradation in G1 (high NHEJ) phase of cell cycle.	commercially available).		
	- Can be transiently expressed from plasmid.			
B. Enrichment for HDR biased cells				
Co-insertion of integrated selectable marker	- Integration of puromycin resistance gene at safe	- Selectable marker must be removed for scarless	[39,40]	
	harbor locus in addition to the target edit.	editing.		
	- Selection for one HDR event is correlated with	- Additional Cas9 and sgRNA must be targeted to		
	additional HDR events.	safe harbor site.		
		- Potential off-target DSBs.		
C. Repair pathway modulation				
Factors for inhibition of NHEJ or promotion	- Co-delivery of some small molecules or other	- Effectiveness varies from cell line to cell line.	[16,41–43]	
of HDR	factors (SCR7, L755507, etc.) shown to increase	- Toxicity of some factors reported in specific hPSC		
	HDR/NHEJ ratio.	lines.		
D. Improved design of donor DNA				
Use of single stranded DNA donors	- Insertion of sequences up to ${\sim}30$ nt.	- ssODNs incorporated via HDR, not efficient in	[62]	
(ssODN) vs. double stranded DNA	- ssODNs can be synthesized rapidly without	post-mitotic cells.		
	cloning.	- Not suitable for large constructs, synthesis of long		
	<ul> <li>ssDNA has less probability of off-target integration</li> </ul>	ssODNs for synthetic gene insertion is only recently		
	vs dsDNA donors.	reported.		
Use of asymmetric homology arms for	- ssODNs with one short arm ( $\sim$ 30 nt) and one	- short ssDNA less stable than dsDNA (improve	[27,44]	
ssODN	longer arm ( $\sim$ 70 nt) have higher integration	stability with phosphorothiorate bonds but increase		
	efficiency due to 5'-3' exonuclease activity or strand	cytotoxicity).		
	release by Cas9.			

Table I (Continued)

Method	Advantages	Disadvantages	Examples
3. Identifying precisely-edited clones from	n a mixed population		
A. Deep sequencing/high-throughput sequencing (H	HTS) based		
HTS Library Preparation	<ul> <li>Commercially available DNA barcoding library kits enable genotyping of 96 or more clonal populations</li> </ul>	<ul> <li>Most HTS reads only 100–200 nt in length;</li> <li>possibility of incorrectly genotyping clones due to</li> </ul>	[46]
	on single HTS lane.	undetected large deletions.	
B. Non-deep sequencing based			
Digital droplet PCR	<ul> <li>Identification of rare sequences in mixed population.</li> <li>Enables targeted subcloning to isolate preciselyedited clones.</li> </ul>	<ul> <li>Requires specialized equipment.</li> <li>Primer used for detection of precise edit must be optimized for each locus.</li> </ul>	[47,48]
Capillary electrophoresis of labeled	- Uses Sanger sequencing capillaries to identify indels	- Difficult to detect rare edited alleles in a mixed	[49,50]
amplicons	and/or base changes Can be less costly vs ddPCR or HTS.	population compared to HTS or ddPCR.	
C. Scarless integration of selectable markers			
piggyBac Transposon	<ul> <li>piggyBac flanked sequences can be used to completely remove pos/neg</li> <li>(fluorophore + puro∆tk) selection cassette.</li> <li>FACS can enable isolation of polyclonal precise edited populations</li> </ul>	<ul> <li>Methods require a second treatment step to remove selection cassette.</li> <li>piggyBac repeat sequences may increase off-target integration; careful donor design is needed.</li> </ul>	[52,53]
D. Prevention of additional on target edits			
CORRECT Method	<ul> <li>Integrate blocking mutation along with intended edit to prevent Cas9 re-cutting.</li> <li>Homozygous vs heterozygous insertion can be predicted by distance of intended edit from DSB site.</li> </ul>	<ul> <li>Requires second editing step with new ssODN and sgRNA or new ssODN with modified PAM Cas9 variant for scarless editing.</li> </ul>	[54]

sensitivity of hPSC lines to singularization [31]. In cell lines recalcitrant to FACS, transient puromycin selection serves as viable alternative [30].

Importantly, extended exposure to high levels of Cas9—as expected in stable expression lines or stringent enrichment methods—has been shown to increase the probability of offtarget DSB formation. Off-target DSBs are an important consideration, as undefined indels throughout the genome can confound phenotypic outputs of disease models. Fortunately, sgRNA design algorithms [32,33], high fidelity [34,35], and nickase [36] Cas9 variants have been shown to decrease offtarget editing, in some cases, at the expense of some on-target efficacy.

# Increasing HDR to NHEI ratio

In hPSCs, imprecise NHEJ is heavily favored over HDR during repair of Cas9 induced DSBs. Improving the HDR to NHEJ ratio improves the efficiency of precise editing workflows and has been accomplished by harnessing or manipulating intrinsic DSB repair processes. Delivering Cas9 protein only during the S and G2 phase of the cell cycle, when HDR pathways are most active, was shown to increase HDR efficiency; however, the parameters for cell cycle control varied considerably from cell line to cell line [37]. A related approach conjugates a peptide to Cas9 which targets Cas9 for selective degradation during the G1 phase of the cell cycle, when NHEJ predominates [38]. More recently, enrichment for cells that are presumably in an HDR biased state was performed by coinserting a drug selectable marker at a secondary safe harbor locus [39,40]. Co-insertion methods appear to be more effective than direct manipulation of the cell cycle, but they require generation of DSBs at additional genomic loci and can result in permanent integration of the selection cassette. Identification of small molecule or other targeted factors that inhibit NHEJ or promote HDR has also demonstrated increased HDR/NHEJ editing ratios in several reports [16,41-43]. However, it is not clear if these factors are tolerated or are universally effective across hPSC lines [27,41].

Other efforts have focused on optimizing donor DNA construction and improving its co-localization with the nuclease to stimulate HDR. Early work demonstrated that optimal single-stranded oligonucleotide (ssODN) donor length is approximately 70-120 nt, and that changes encoded in the donor DNA are more likely to be integrated when the changes are near the DSB site [31]. Work by Richardson et al. demonstrated that sidedness of the DNA strand used as the ssODN template and asymmetric lengths of homology arms can be used to increase HDR efficiency [44]. Later reports reinforce the value of asymmetric homology arms, but did not see improvements by selecting the template strand [27]. Prevention of ssODN degradation with the use of phosphorothioatemodified oligonucleotides has also been shown to enhance HDR efficiency in cultured cells, presumably by stabilizing the ssODN within cells and during delivery [45].

#### Identifying precisely-edited clones from a mixed population

A major obstacle for isolating precisely genome-edited clones is identifying them from a mixed population. Many workflows utilize high-throughput or deep sequencing library preparation methods to sequence many unique clones in parallel on a single lane [46]. Non-deep sequencing techniques include digital droplet PCR (ddPCR) [47,48] and fluorescent gel capillary based methods [49,50]. These methods require working with a high number of clonal cell linestypically over a hundred—but they can be combined with methods that increase editing efficiency or HDR/NHEJ ratios to improve workflows [51]. Recently, PiggyBac transposon [52,53] methods have been used to integrate selectable markers that can be used to enrich for precisely-edited hPSCs before being completely removed to yield scarless editing. These methods are efficient for selecting precisely edited clones, but the requirement for temporary introduction of a selection cassette transiently disrupts endogenous gene expression, which prevents their use in essential genes or those involved in maintenance of pluripotency.

A major hurdle for precise editing of clones has been isolating clones without additional on-target indels. This is especially challenging when heterozygous mutant lines (one allele mutated, the other allele unedited/WT) are desired. One solution, presented by Paquet et al. [54], involves a two-step process where both the intended mutation and a blocking mutation are made with the first ssODN repair. The blocking mutation prevents re-cutting of the repaired template and can be removed by a subsequent editing step using a newly designed sgRNA, or the same sgRNA with a Cas variant with different PAM specificity. This method requires repeated editing steps, but may be necessary for generation of precise heterozygous mutants.

# **Outlook**

The development of more representative disease models and genome editing methods with higher throughput and efficiency could advance these models further. First, organoid and engineered co-culture technologies [55] could recapitulate tissue/organ function more faithfully than 2D cultures. For example, Dekkers et al. found that drug treatment response of cystic fibrosis (CF) patient-derived gut organoids mimicked the response of different patients with those same mutations in an in-human CF clinical trial [56]. Second, highthroughput genome editing methods, including genomewide loss of function screens, primarily rely on imprecise NHEJ-mediated DNA repair (reviewed in Ref. [57]). These techniques provide valuable high level data on gene function, but are primarily limited to survival or cell death phenotypes. Further, most employ non-hPSC cell lines to ensure

9

technical viability (as these tend to have higher gene-editing efficiency) at the expense of biological relevance. Findlay and colleagues presented a strategy for high-throughput precision HDR mediated genome editing to determine the effect of precise gene variants on transcription level for the *BRCA1* gene in immortalized HEK 293T cells [58]. Precision HDR within cancer cell lines also enabled target validation for several small molecules [59]. Future improvements in scarless editing efficiency within hPSCs may enable such high-throughput editing to be performed within stem cell derived models.

Investment in hPSC disease modeling strategies is contingent not only on technical advances, but also regulatory acceptance of these models. In the US, the FDA has signaled that cell based models may play an increasing role in future drug approvals, especially for rare diseases, by supplementing or even substituting for clinical trial data [60]. A dramatic example is the on label approval of the CF drug ivacaftor for twenty three additional CF mutations (ten originally) based on cell based assays alone [61]. Reliance on cell-based assays in lieu of clinical trial data will likely be limited to rare cases; tradeoffs in drug access and patient safety must also be carefully considered. More likely, genome-edited stem cell derived disease models will play a role in generating preclinical data for precision medicine trials. There is an immediate role in drug repurposing, where the therapeutic potential of approved compounds or those previously shown to be safe in Phase I trials could be screened in genotype-specific models. Consideration of smaller or modified clinical trials based on precisely edited hPSC-derived disease model data could incentivize therapeutic development for rare or biomarker specific subsets of common diseases. Given the recent advances in generating genome-edited disease models, it is highly likely that evidence from such models will be increasingly used in the drug discovery pipeline for precision therapies.

# Acknowledgements

This work was supported by the NSF [CBET-1350178 to K.S., CBET-1645123 to K.S.]; the NIH [1R35GM119644-01 to K.S., 4T32HG002760-14 to B.S., 1F30EY027699-01 to B.S.]; the VitreoRetinal Surgery Foundation to B.S, the John Merck Fund [Translational Research Program to K.S.]; Brain & Behavior Research Foundation [K.S.]; Burroughs Wellcome Fund [K.S.]. Additionally, we thank all members of the Saha lab for helpful discussion and comments on the manuscript.

#### References

- Clinical Development Success Rates 2006–2015 BIO, Biomedtracker, Amplion 2016. https://www.bio.org/sites/default/files/Clinical Development Success Rates 2006-2015 - BIO, Biomedtracker, Amplion 2016.pdf. [Accessed 13 November 2017].
- [2] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by

- defined factors. Cell 2007;131:861–72. <a href="http://dx.doi.org/10.1016/j.cell.2007.11.019">http://dx.doi.org/10.1016/j.cell.2007.11.019</a>.
- [3] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917–20. <a href="http://dx.doi.org/10.1126/science.1151526">http://dx.doi.org/10.1126/science.1151526</a>.
- [4] Singh R, Shen W, Kuai D, Martin JM, Guo X, Smith MA, et al. iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration. Hum Mol Genet 2013;22:593–607. http://dx.doi.org/10.1093/hmg/dds469.
- [5] Singh R, Kuai D, Guziewicz KE, Meyer J, Wilson M, Lu J, et al. Pharmacological modulation of photoreceptor outer segment degradation in a human iPS cell model of inherited macular degeneration. Mol Ther 2015;23:1700–11. http://dx.doi.org/10.1038/mt.2015.141.
- [6] Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol 2016;17:170–82. <a href="http://dx.doi.org/10.1038/nrm.2015.27">http://dx.doi.org/10.1038/nrm.2015.27</a>.
- [7] Warren CR, Cowan CA. Humanity in a Dish: Population Genetics with iPSCs. Trends Cell Biol 2018;28:46–57. <a href="http://dx.doi.org/10.1016/j.tcb.2017.09.006">http://dx.doi.org/10.1016/j.tcb.2017.09.006</a>.
- [8] Burridge PW, Li YF, Matsa E, Wu H, Ong S-G, Sharma A, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 2016;22:547–56. <a href="http://dx.doi.org/10.1038/nm.4087">http://dx.doi.org/10.1038/nm.4087</a>.
- [9] Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 2013;155:1351–64. http://dx.doi.org/10.1016/j.cell.2013.11.009.
- [10] Sala L, Yu Z, Ward-van Oostwaard D, van Veldhoven JP, Moretti A, Laugwitz K-L, et al. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Mol Med 2016;8:1065–81. http://dx.doi.org/10.15252/emmm.201606260.
- [11] Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 2014;20:616. <a href="http://dx.doi.org/10.1038/nm.3545">http://dx.doi.org/10.1038/nm.3545</a>.
- [12] Zhu Z, Verma N, González F, Shi Z-D, Huangfu D. A CRISPR/Cas-mediated selection-free knockin strategy in human embryonic stem cells. Stem Cell Rep 2015;4:1103–11. <a href="http://dx.doi.org/10.1016/j.stemcr.2015.04.016">http://dx.doi.org/10.1016/j.stemcr.2015.04.016</a>.
- [13] Zhao W, Siegel D, Biton A, Tonqueze OL, Zaitlen N, Ahituv N, et al. CRISPR-Cas9-mediated functional dissection of 3'-UTRs. Nucleic Acids Res 2017;45:10800-10. <a href="http://dx.doi.org/10.1093/nar/gkx675">http://dx.doi.org/10.1093/nar/gkx675</a>.
- [14] Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23. <a href="http://dx.doi.org/10.1126/science.1231143">http://dx.doi.org/10.1126/science.1231143</a>.
- [15] Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823–6. <a href="http://dx.doi.org/10.1126/science.1232033">http://dx.doi.org/10.1126/science.1232033</a>.
- [16] Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 2015;33:538–42. <a href="http://dx.doi.org/10.1038/nbt.3190">http://dx.doi.org/10.1038/nbt.3190</a>.
- [17] O'Driscoll M, Jeggo PA. The role of double-strand break repair insights from human genetics. Nat Rev Genet 2006;7:45–54. <a href="http://dx.doi.org/10.1038/nrg1746">http://dx.doi.org/10.1038/nrg1746</a>.
- [18] Zou J, Mali P, Huang X, Dowey SN, Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011;118:4599–608. <a href="http://dx.doi.org/10.1182/blood-2011-02-335554">http://dx.doi.org/10.1182/blood-2011-02-335554</a>.
- [19] Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009;27:851–7. <a href="http://dx.doi.org/10.1038/nbt.1562">http://dx.doi.org/10.1038/nbt.1562</a>.
- [20] Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee Y-L, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and

- integrase-defective lentiviral vector delivery. Nat Biotechnol 2007;25:1298–306. http://dx.doi.org/10.1038/nbt1353.
- [21] Dow LE, Fisher J, O'Rourke KP, Muley A, Kastenhuber ER, Livshits G, et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 2015;33:390–4. http://dx.doi.org/10.1038/nbt.3155.
- [22] Wang G, Yang L, Grishin D, Rios X, Ye LY, Hu Y, et al. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies. Nat Protoc 2017;12:88–103. <a href="http://dx.doi.org/10.1038/nprot\_2016.152">http://dx.doi.org/10.1038/nprot\_2016.152</a>.
- [23] Steyer B, Carlson-Stevermer J, Angenent-Mari N, Khalil A, Harkness T, Saha K. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells. Acta Biomater 2016;34:143–58. http://dx.doi.org/10.1016/j.actbio.2015.12.036.
- [24] González F, Zhu Z, Shi Z-D, Lelli K, Verma N, Li QV, et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 2014;15:215–26. <a href="http://dx.doi.org/10.1016/j.stem.2014.05.018">http://dx.doi.org/10.1016/j.stem.2014.05.018</a>.
- [25] Cao J, Wu L, Zhang S-M, Lu M, Cheung WKC, Cai W, et al. An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting. Nucleic Acids Res 2016;44e149. <a href="http://dx.doi.org/10.1093/nar/gkw660">http://dx.doi.org/10.1093/nar/gkw660</a>.
- [26] Xie Y, Wang D, Lan F, Wei G, Ni T, Chai R, et al. An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells. Sci Rep 2017;7:2320. <a href="http://dx.doi.org/10.1038/s41598-017-02456-y">http://dx.doi.org/10.1038/s41598-017-02456-y</a>.
- [27] Liang X, Potter J, Kumar S, Ravinder N, Chesnut JD. Enhanced CRISPR/ Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. J Biotechnol 2017;241:136–46. http://dx.doi.org/10.1016/j.jbiotec.2016.11.011.
- [28] Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8:2281–308. http://dx.doi.org/10.1038/nprot.2013.143.
- [29] Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 2013;12:393–4. <a href="http://dx.doi.org/10.1016/j.stem.2013.03.006">http://dx.doi.org/10.1016/j.stem.2013.03.006</a>.
- [30] Steyer B, Bu Q, Cory E, Jiang K, Duong S, Sinha D, et al. Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection. Stem Cell Rep 2018;10:642–54. <a href="http://dx.doi.org/10.1016/j.stemcr.2017.12.004">http://dx.doi.org/10.1016/j.stemcr.2017.12.004</a>.
- [31] Yang L, Guell M, Byrne S, Yang JL, Angeles ADL, Mali P, et al. Optimization of scarless human stem cell genome editing. Nucleic Acids Res 2013;41:9049–61. <a href="http://dx.doi.org/10.1093/nar/gkt555">http://dx.doi.org/10.1093/nar/gkt555</a>.
- [32] Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013;31:827–32. http://dx.doi.org/10.1038/nbt.2647.
- [33] Kim HK, Min S, Song M, Jung S, Choi JW, Kim Y, et al. Deep learning improves prediction of CRISPR-Cpf1 guide RNA activity. Nature Biotechnol 2018. <u>http://dx.doi.org/10.1038/nbt.4061</u>.
- [34] Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 2016;529. <a href="http://dx.doi.org/10.1038/nature16526">http://dx.doi.org/10.1038/nature16526</a>. nature16526.
- [35] Casini A, Olivieri M, Petris G, Montagna C, Reginato G, Maule G, et al. A highly specific SpCas9 variant is identified by in vivo screening in yeast. Nature Biotechnol 2018. <a href="http://dx.doi.org/10.1038/nbt.4066">http://dx.doi.org/10.1038/nbt.4066</a>.
- [36] Ran FA, Hsu PD, Lin C-Y, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing specificity. Cell 2013;154:1380–9. <a href="http://dx.doi.org/10.1016/j.cell.2013.08.021">http://dx.doi.org/10.1016/j.cell.2013.08.021</a>.
- [37] Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 2014;3e04766. <a href="http://dx.doi.org/10.7554/eLife.04766">http://dx.doi.org/10.7554/eLife.04766</a>
- [38] Howden SE, McColl B, Glaser A, Vadolas J, Petrou S, Little MH, et al. A Cas9 Variant for Efficient Generation of Indel-Free Knockin or Gene-Corrected Human Pluripotent Stem Cells. Stem Cell Rep 2016;7:508–17. <a href="http://dx.doi.org/10.1016/j.stemcr.2016.07.001">http://dx.doi.org/10.1016/j.stemcr.2016.07.001</a>.

- [39] Mitzelfelt KA, McDermott-Roe C, Grzybowski MN, Marquez M, Kuo C-T, Riedel M. Efficient precision genome editing in iPSCs via genetic cotargeting with selection. Stem Cell Rep 2017;8:491–9. <a href="http://dx.doi.org/10.1016/j.stemcr.2017.01.021">http://dx.doi.org/10.1016/j.stemcr.2017.01.021</a>.
- [40] Shy BR, MacDougall MS, Clarke R, Merrill BJ. Co-incident insertion enables high efficiency genome engineering in mouse embryonic stem cells. Nucleic Acids Res 2016;44:7997–8010. <a href="http://dx.doi.org/10.1093/nar/gkw685">http://dx.doi.org/10.1093/nar/gkw685</a>.
- [41] Song J, Yang D, Xu J, Zhu T, Chen YE, Zhang J. RS-1 enhances CRISPR/ Cas9- and TALEN-mediated knock-in efficiency. Nat Commun 2016;7:10548. http://dx.doi.org/10.1038/ncomms10548.
- [42] Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol 2015;33:543–8. http://dx.doi.org/10.1038/nbt.3198.
- [43] Yu C, Liu Y, Ma T, Liu K, Xu S, Zhang Y, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 2015;16:142–7. <a href="http://dx.doi.org/10.1016/j.stem.2015.01.003">http://dx.doi.org/10.1016/j.stem.2015.01.003</a>.
- [44] Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol 2016;34:339– 44. http://dx.doi.org/10.1038/nbt.3481.
- [45] Renaud J-B, Boix C, Charpentier M, De Cian A, Cochennec J, Duvernois-Berthet E, et al. Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPR-Cas9 nucleases. Cell Rep 2016;14:2263–72. http://dx.doi.org/10.1016/j.celrep.2016.02.018.
- [46] Byrne SM, Church GM. Crispr-mediated gene targeting of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol 2015;35:1–22. <a href="http://dx.doi.org/10.1002/9780470151808">http://dx.doi.org/10.1002/9780470151808</a>. 5A.8. sc05a08s35.
- [47] Miyaoka Y, Chan AH, Judge LM, Yoo J, Huang M, Nguyen TD, et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat Methods 2014;11:291–3. <a href="http://dx.doi.org/10.1038/nmeth.2840">http://dx.doi.org/10.1038/nmeth.2840</a>.
- [48] Findlay SD, Vincent KM, Berman JR, Postovit L-M. A digital PCR-based method for efficient and highly specific screening of genome edited cells. PLoS One 2016;11e0153901. <a href="http://dx.doi.org/10.1371/journal.pone.0153901">http://dx.doi.org/10.1371/journal.pone.0153901</a>.
- [49] Yang Z, Steentoft C, Hauge C, Hansen L, Thomsen AL, Niola F, et al. Fast and sensitive detection of indels induced by precise gene targeting. Nucleic Acids Res 2015;43e59. <a href="http://dx.doi.org/10.1093/nar/gkv126">http://dx.doi.org/10.1093/nar/gkv126</a>.
- [50] Ramlee MK, Yan T, Cheung AMS, Chuah CTH, Li S. High-throughput genotyping of CRISPR/Cas9-mediated mutants using fluorescent PCRcapillary gel electrophoresis. Sci Rep 2015;5. <a href="http://dx.doi.org/10.1038/srep15587">http://dx.doi.org/10.1038/srep15587</a>.
- [51] Lonowski LA, Narimatsu Y, Riaz A, Delay CE, Yang Z, Niola F, et al. Genome editing using FACS enrichment of nuclease-expressing cells and indel detection by amplicon analysis. Nat Protoc 2017;12:581–603. <a href="http://dx.doi.org/10.1038/nprot.2016.165">http://dx.doi.org/10.1038/nprot.2016.165</a>.
- [52] Arias-Fuenzalida J, Jarazo J, Qing X, Walter J, Gomez-Giro G, Nickels SL, et al. FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling. Stem Cell Rep 2017;9:1423–31. <a href="http://dx.doi.org/10.1016/j.stemcr.2017.08.026">http://dx.doi.org/10.1016/j.stemcr.2017.08.026</a>.
- [53] Eggenschwiler R, Moslem M, Fráguas MS, Galla M, Papp O, Naujock M, et al. Improved bi-allelic modification of a transcriptionally silent locus in patient-derived iPSC by Cas9 nickase. Sci Rep 2016;6. <a href="http://dx.doi.org/10.1038/srep38198">http://dx.doi.org/10.1038/srep38198</a>. srep38198.
- [54] Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 2016;533:125–9. <a href="http://dx.doi.org/10.1038/nature17664">http://dx.doi.org/10.1038/nature17664</a>.
- [55] Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol 2014;32. http://dx.doi.org/10.1038/nbt.2989. nbt.2989.
- [56] Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med 2016;8. http://dx.doi.org/10.1126/scitranslmed.aad8278. 344ra84.

- [57] Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet 2015;16. <a href="http://dx.doi.org/10.1038/nrg3899">http://dx.doi.org/10.1038/nrg3899</a>. nrg3899.
- [58] Findlay GM, Boyle EA, Hause RJ, Klein JC, Shendure J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 2014;513:120–3. http://dx.doi.org/10.1038/nature13695.
- [59] Smurnyy Y, Cai M, Wu H, McWhinnie E, Tallarico JA, Yang Y, et al. DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells. Nat Chem Biol 2014;10:623–5. <a href="http://dx.doi.org/10.1038/nchembio.1550">http://dx.doi.org/10.1038/nchembio.1550</a>.
- [60] O. of the Commissioner, Press Announcements FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis, (n.d.). https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm559212.htm. [Accessed 4 November 2017].
- [61] KALYDECO (ivacaftor) Label, (n.d.). https://www.accessdata.fda.gov/drugsatfda\_docs/label/2017/203188s019lbl.pdf. [Accessed 4 November 2017].
- [62] Li H, Beckman KA, Pessino V, Huang B, Weissman JS, Leonetti MD. Design and specificity of long ssDNA donors for CRISPR-based knock-in. bioRxiv 2017;178905. <u>http://dx.doi.org/10.1101/178905</u>.